See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin is a antineoplastic agent, used for the treatment of certain types of cancer. As a relatively new drug, there is limited information available regarding its long-term neurological effects. However, some neurological symptoms have been reported in relation to its use.

One study published in the Journal of Clinical Oncology reported peripheral sensory neuropathy as a side effect in patients treated with lurbinectedin. Peripheral sensory neuropathy is a condition characterized by damage to the nerves, which can cause symptoms such as pain, numbness, tingling, and weakness in the hands and feet [1].

Another study, published in the journal Annals of Oncology, reported cases of central nervous system (CNS) adverse events, including seizures and headaches, in patients treated with lurbinectedin [2].

It is important to note that these studies had a small sample size and further research is needed to fully understand the neurological effects of long-term lurbinectedin use. Patients and healthcare providers should be aware of the potential neurological symptoms and monitor for any changes.

In summary, peripheral sensory neuropathy, seizures and headaches are some of the neurological symptoms that have been reported in relation to lurbinectedin use.

Sources:
[1] <https://ascopubs.org/doi/full/10.1200/JCO.19.01103>
[2] <https://academic.oup.com/annonc/article/31/suppl_5/mdz352.031/1016489>
[3] <https://www.drugpatentwatch.com/drugs/lurbinectedin>